Caribou Biosciences, Inc. (CRBU)Healthcare | Biotechnology | Berkeley, United States | NasdaqGS
2.20 USD
+0.05
(2.326%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.24 +0.04 (1.918%) ⇧ (April 17, 2026, 7:29 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:55 p.m. EDT
CRBU is a high-risk, high-reward stock with a volatile price history and no dividend payouts. The recent news and analyst upgrades suggest some optimism about its potential, but the lack of consistent earnings and the high beta indicate significant risk. The short-term options data shows mixed signals, with both bullish and bearish positions, making it difficult to determine a clear direction. Long-term investors should approach with caution, as the fundamentals are weak and the stock is highly speculative. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.166911 |
| AutoETS | 0.166912 |
| MSTL | 0.171142 |
| AutoTheta | 0.308143 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.224 |
| Excess Kurtosis | -0.83 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.285 |
| Revenue per Share | 0.119 |
| Market Cap | 212,601,840 |
| Forward P/E | -1.47 |
| Beta | 2.46 |
| Website | https://cariboubio.com |
As of April 11, 2026, 2:55 p.m. EDT: Options speculators are showing mixed signals. Calls have higher open interest and volatility, especially around the $2.5 strike, suggesting some bullish sentiment. However, puts also show significant activity, particularly around the $2.5 strike, which may indicate caution or bearish positioning. The ATM strikes are relatively stable, but the overall volatility and open interest suggest uncertainty about the stock's direction in the short term.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7672956 |
| Address1 | 2,929 7th Street |
| Address2 | Suite 105 |
| All Time High | 32.645 |
| All Time Low | 0.66 |
| Ask | 2.26 |
| Ask Size | 11 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,397,620 |
| Average Daily Volume3 Month | 1,272,209 |
| Average Volume | 1,272,209 |
| Average Volume10Days | 1,397,620 |
| Beta | 2.463 |
| Bid | 2.15 |
| Bid Size | 11 |
| Book Value | 1.284 |
| City | Berkeley |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.2 |
| Current Ratio | 5.715 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.2578 |
| Day Low | 2.14 |
| Debt To Equity | 22.285 |
| Display Name | Caribou Biosciences |
| Earnings Timestamp | 1,772,744,400 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -130,273,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.771 |
| Enterprise To Revenue | 9.005 |
| Enterprise Value | 100,488,848 |
| Eps Current Year | -1.38 |
| Eps Forward | -1.5 |
| Eps Trailing Twelve Months | -1.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.858 |
| Fifty Day Average Change | 0.342 |
| Fifty Day Average Change Percent | 0.18406889 |
| Fifty Two Week Change Percent | 176.72955 |
| Fifty Two Week High | 3.535 |
| Fifty Two Week High Change | -1.335 |
| Fifty Two Week High Change Percent | -0.37765205 |
| Fifty Two Week Low | 0.73 |
| Fifty Two Week Low Change | 1.47 |
| Fifty Two Week Low Change Percent | 2.0136986 |
| Fifty Two Week Range | 0.73 - 3.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,047,000,000 |
| Float Shares | 92,267,268 |
| Forward Eps | -1.5 |
| Forward P E | -1.4666667 |
| Free Cashflow | -69,796,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 97 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -96,364,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09665 |
| Held Percent Institutions | 0.37636003 |
| Implied Shares Outstanding | 96,637,202 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. |
| Long Name | Caribou Biosciences, Inc. |
| Market | us_market |
| Market Cap | 212,601,840 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_272189231 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -148,124,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 213,085,030 |
| Number Of Analyst Opinions | 8 |
| Open | 2.2 |
| Operating Cashflow | -110,992,000 |
| Operating Margins | -7.21974 |
| Payout Ratio | 0.0 |
| Phone | 510 982 6030 |
| Post Market Change | 0.04219985 |
| Post Market Change Percent | 1.918175 |
| Post Market Price | 2.2422 |
| Post Market Time | 1,776,468,585 |
| Previous Close | 2.15 |
| Price Eps Current Year | -1.594203 |
| Price Hint | 4 |
| Price To Book | 1.7133956 |
| Price To Sales Trailing12 Months | 19.052052 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.6 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 2.32558 |
| Regular Market Day High | 2.2578 |
| Regular Market Day Low | 2.14 |
| Regular Market Day Range | 2.14 - 2.2578 |
| Regular Market Open | 2.2 |
| Regular Market Previous Close | 2.15 |
| Regular Market Price | 2.2 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,803,872 |
| Return On Assets | -0.34255 |
| Return On Equity | -0.78973 |
| Revenue Growth | 0.897 |
| Revenue Per Share | 0.119 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 96,637,202 |
| Shares Percent Shares Out | 0.067 |
| Shares Short | 6,472,632 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,232,010 |
| Short Name | Caribou Biosciences, Inc. |
| Short Percent Of Float | 0.07 |
| Short Ratio | 5.81 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRBU |
| Target High Price | 32.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 11.125 |
| Target Median Price | 8.5 |
| Total Cash | 139,340,000 |
| Total Cash Per Share | 1.442 |
| Total Debt | 27,227,000 |
| Total Revenue | 11,159,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.913975 |
| Two Hundred Day Average Change | 0.28602505 |
| Two Hundred Day Average Change Percent | 0.14944032 |
| Type Disp | Equity |
| Volume | 1,803,872 |
| Website | https://cariboubio.com |
| Zip | 94,710 |